Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

Published byErik Newman Modified over 6 years ago

Similar presentations

Presentation on theme: "A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in."— Presentation transcript:

1 A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women  Ulrike Blume-Peytavi, MD, PhD, Kathrin Hillmann, MD, Ekkehart Dietz, PhD, Douglas Canfield, Natalie Garcia Bartels, MD  Journal of the American Academy of Dermatology  Volume 65, Issue 6, Pages e2 (December 2011) DOI: /j.jaad Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Participant disposition. One drug-unrelated serious adverse event (SAE) in 5% minoxidil topical foam (MTF) population. AE, Adverse event; LTF, lost to follow-up; MTS, minoxidil topical solution; SP, subject preference. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Nonvellus target area hair count (TAHC). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Nonvellus target area hair width (TAHW). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Nonvellus target area hair count (TAHC) at week 24 change from baseline is lower with increasing severity of Savin score among all participants randomized to 5% minoxidil topical foam or 2% minoxidil topical solution. Lowest TAHC is obtained in women with highest Savin score (D6) (Savin scale ranges from D1-D8, current study recruited women with Savin grade D3-D6). Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Global change in hair volume based on global photographs of scalp midpattern comparing baseline and week 24 by investigators' (A) and participants' (B) evaluation (–3 = greatly decreased, –2 = moderately decreased, –1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, and +3 = greatly increased). MTF, Minoxidil topical foam; MTS, minoxidil topical solution. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

7 Fig 6 Distribution of responses to statement 6 of participants' questionnaire 2 (“The treatment does not interfere with styling my hair”). Responses range from 1 = totally disagree to 7 = totally agree. MTF, Minoxidil topical foam; MTS, minoxidil topical solution; ND, no data. Journal of the American Academy of Dermatology  , e2DOI: ( /j.jaad ) Copyright © 2010 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Use of the diagonal mattress suture to prevent dog-ear formation

Use of the diagonal mattress suture to prevent dog-ear formation
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,

Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
A girl with a solitary red bulla

A girl with a solitary red bulla
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Focal nail dystrophy in a cutaneous nerve distribution after trauma

Focal nail dystrophy in a cutaneous nerve distribution after trauma
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
Permanent chemotherapy-induced alopecia: A review

Permanent chemotherapy-induced alopecia: A review
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Similar presentations

Ads by Google